GSK's Jideytro Achieves 94% Objective Response Rate At 15.2 Months Follow-Up In TKI-Naïve ROS1-Positive NSCLC, ARROS-1 Trial Shows
Benzinga Newsdesk 1 month ago
News
94% objective response rate at 15.2 months follow-up90% of patients were progression free at 12 months, with median PFS rate still to be reached70% of patients with measurable brain metastases achieved complete
- 94% objective response rate at 15.2 months follow-up
- 90% of patients were progression free at 12 months, with median PFS rate still to be reached
- 70% of patients with measurable brain metastases achieved complete clearance of detectable brain tumours
- Results support potential to address key efficacy and tolerability needs in ROS1-positive NSCLC with US regulatory submission planned in 2026